Postmastectomy radiotherapy: Will the selective use of postmastectomy radiotherapy study end the debate?

Journal of Clinical Oncology

Volumn 27, Issue 6, 2009, Pages 996-997

  Russell, Nicola S ^a   Kunkler, Ian H ^b   Van Tienhoven, Geertjan ^c   Canney, Peter A ^d   Thomas, Jeremy ^b   Bartlett, John ^b   Van De Vijver, Marc J ^c   Belkacemi, Yazid ^e   Yarnold, John R ^f   Barrett Lee, Peter J ^g  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^e HENRI MONDOR HOSPITAL   (France)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g Velindre NHS Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; GENETIC ANALYSIS; HUMAN; LETTER; MOLECULAR GENETICS; OUTCOME ASSESSMENT; POSTMASTECTOMY RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; TUMOR CLASSIFICATION;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS;

EID: 60849125121     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.7062     Document Type: Letter

References (27)

1. Marks LB, Zeng J, Prosnitz LR: One to three versus four or more positive nodes and postmastectomy radiotherapy: Time to end the debate. J Clin Oncol 26:2075-2077, 2008
2. Gebski V, Lagleva M, Keech A, et al: Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: A clinical perspective. J Natl Cancer Inst 98:26-38, 2006
3. Poortmans P: Evidence based radiation oncology: Breast cancer. Radiother Oncol 84:84-101, 2007
4. Kunkler IH, Canney P, van TG, et al: Elucidating the role of chest wall irradiation in 'intermediate-risk' breast cancer: The MRC/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol) 20:31-34, 2008
5. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials-Early Breast Cancer Trialists' Collaborative Group. Lancet 355:1757-1770, 2000
6. Recht A, Gray R, Davidson NE, et al: Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group. J Clin Oncol 17:1689-1700, 1999
7. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
8. Coates AS, Keshaviah A, Thurlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J ClinOncol 25:486-492, 2007
9. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
10. Forbes JF, Cuzick J, Buzdar A, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
11. Goss PE, Ingle JN, Martino S, et al: Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 25:2006-201 1, 2007
12. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998
13. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
14. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled
15. trial. Lancet 369:29-36, 2007
16. Thurlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
17. Ward S, Simpson E, Davis S, et al: Taxanes for the adjuvant treatment of early breast cancer: Systematic review and economic evaluation. Health Technol Assess 11:1-144, 2007
18. Woodward WA, Vinh-Hung V, Ueno NT, et al: Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol 24:2910-2916, 2006
19. Van de Steene J, Soete G, Storme G: Adjuvant radiotherapy for breast cancer significantly improves overall survival: The missing link. Radiother Oncol 55:263-272, 2000
20. Van de Steene J, Vinh-Hung V, Cutuli B, et al: Adjuvant radiotherapy for breast cancer: Effects of longer follow-up. Radiother Oncol 72:35-43, 2004
21. Cardoso F, Van't VL, Rutgers E, et al: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 26:729-735, 2008
22. Nguyen PL, Taghian AG, Katz MS, et al: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378, 2008
23. Kyndi M, Overgaard M, Nielsen HM, et al: High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: A subgroup analysis of DBCG 82 b&c. Radiother Oncol [epub ahead of print on May 7, 2008]
24. Kyndi M, Sorensen FB, Knudsen H, et al: Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 26:1419-1426, 2008
25. Nuyten DS, Kreike B, Hart AA, et al: Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res
26. 8:R62, 2006
27. National Health Service Scotland. MRC Supremo Trial. wrww.supremo-trial. com